Tempus AI

Tempus AI is a technology company advancing precision medicine by combining AI with one of the world's largest libraries of clinical and molecular data. The company has built a dataset of over 7 million de-identified patient records with matched genomic, transcriptomic, and clinical outcome data, enabling AI models that help physicians make more informed treatment decisions.

Tempus offers genomic profiling tests that sequence patients' tumors and use AI to identify relevant biomarkers, match patients to clinical trials, and suggest targeted therapies. The company's AI platform serves oncologists, researchers, and pharmaceutical companies, providing insights that accelerate drug development and improve patient outcomes.

The company went public in 2024 and has expanded beyond oncology into cardiology, radiology, and mental health. Tempus' data and AI platform is used by a majority of academic medical centers in the US and by leading pharmaceutical companies for drug development and clinical trial optimization.